Zooming in on the schedule of bone-modifying drugs
Mené sur 425 patientes atteintes d'un cancer du sein avec métastases osseuses, cet essai italien de phase III compare l'efficacité et la toxicité de deux modalités d'administration de l'acide zolédronique (une fois toutes les 12 ou 4 semaines)
Debate surrounds the best duration and scheduling of treatment with bone-modifying drugs for patients with breast cancer who have bone metastases. The recommended doses for zoledronic acid and denosumab are specified in the prescribing information of these drugs, but no recommendation is made about the best duration of treatment. In the registration trial of zoledronic acid—in which it was compared with pamidronate—the median duration of treatment was roughly 1 year, although many patients...
The Lancet Oncology , commentaire, 2012